DL Global Partners Inc., Toronto, Canada.
J Psychopharmacol. 2013 Sep;27(9):808-16. doi: 10.1177/0269881113493364. Epub 2013 Jun 19.
Reformulated OxyContin® (oxycodone HCl controlled-release or ORF) was developed as a tamper and abuse-deterrent product, to reduce the risk of product abuse, misuse and their consequences. This noninterventional single-session study asked participants who were medically-healthy recreational opioid users, aged 18 years and older, to consider how they would use commonly available supplies to tamper with placebo ORF and placebo original OxyContin (OC) tablets, and how they would assess the attractiveness of tampering and abusing ORF tablets, as compared with other opioid formulations. Participants provided information on past opioid use, and they assessed the properties of five nonhypothetical oxycodone products and two hypothetical oxycodone products. Participants provided feedback on tampering preferences, preferred tamper methods for each product, overall tampering potential and product preferences. We had 30 participants (27 males and 3 females; mean age 35 years, range 18-51) complete both the interview and tampering sessions. Participants judged OC as the most attractive, valuable, desirable and most likely to be tampered with, from among all opioid products studied. By contrast, they rated ORF as the least attractive, least valuable, least desirable, and least likely to be tampered with among all the nonhypothetical opioid products studied. These results suggested that recreational drug abusers view ORF tablets as tamper-deterrent products.
奥施康定®(盐酸羟考酮控释或 ORF)的重新配方是作为一种防篡改和滥用的产品开发的,以降低产品滥用、误用及其后果的风险。这项非干预性单次研究要求医学健康的娱乐性阿片类药物使用者(年龄 18 岁及以上)考虑他们将如何使用常见的供应品来篡改安慰剂 ORF 和安慰剂原始奥施康定(OC)片剂,以及他们将如何评估篡改和滥用 ORF 片剂的吸引力,与其他阿片类药物制剂相比。参与者提供了过去阿片类药物使用的信息,他们评估了五种非假设性羟考酮产品和两种假设性羟考酮产品的特性。参与者提供了关于篡改偏好、每种产品首选的篡改方法、总体篡改潜力和产品偏好的反馈。我们有 30 名参与者(27 名男性和 3 名女性;平均年龄 35 岁,范围 18-51)完成了访谈和篡改会议。与所有研究的阿片类药物产品相比,参与者认为 OC 是最具吸引力、最有价值、最理想和最有可能被篡改的。相比之下,他们认为 ORF 在所有非假设性阿片类药物产品中是最没有吸引力、最没有价值、最不可取和最不可能被篡改的。这些结果表明,娱乐性药物滥用者将 ORF 片剂视为防篡改产品。